Hormone-Sensitive Prostate Cancer – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hormone-Sensitive Prostate Cancer – Drugs In Development, 2024 report and make more profitable business decisions.
Hormone-sensitive prostate cancer (HSPC) is a type of prostate cancer that responds to hormone therapy, which aims to reduce or block the production or action of androgens such as testosterone. Androgens are male sex hormones that stimulate the growth of normal and cancerous prostate cells. Most prostate cancers are initially hormone-sensitive, but they may become castration-resistant over time, meaning that they continue to grow despite low or undetectable levels of androgens. Hormone therapy for HSPC can slow down the progression of the disease and improve survival outcomes. However, hormone therapy can also cause side effects such as hot flashes, sexual dysfunction, bone loss, fatigue, and mood changes. Therefore, patients with HSPC should discuss the benefits and risks of hormone therapy with their doctors and consider their quality of life and personal preferences when choosing a treatment option.
The Hormone-Sensitive Prostate Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Hormone-Sensitive Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hormone-Sensitive Prostate Cancer and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hormone-Sensitive Prostate Cancer | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 32 molecules, with 27 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hormone-Sensitive Prostate Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hormone-Sensitive Prostate Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hormone-Sensitive Prostate Cancer treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAdvanced Accelerator Applications SA
Antev Ltd
Astellas Pharma Inc
AstraZeneca Plc
Austhera BioSciences Inc
Bavarian Nordic AS
Bristol-Myers Squibb Co
Eli Lilly and Co
Geneos Therapeutics Inc
Herlev Hospital
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori Srl
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Wangao Pharmaceutical Co Ltd
Miami VA Healthcare System
Orion Corp
Pfizer Inc
POINT Biopharma Global Inc
Radboud University
Regeneron Pharmaceuticals Inc
Shenogen Pharma Group Ltd
Shenzhen Neptunus Medical Technology Research Institute Co Ltd
Southwest Jiaotong University
Sumitomo Dainippon Pharma Oncology
Inc
Takeda Pharmaceutical Co Ltd
Tavanta Therapeutics Inc
Ultimovacs AS
Zr Pharma & Gmbh
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Hormone-Sensitive Prostate Cancer reports